secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001683168-23-007582
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma terminates Adva-27a research agreement with JGH after unfavorable lab results
--------------------------------------------------------------------------------

- Termination of Research Agreement with Jewish General Hospital effective Dec 2, 2023.
- Lab results on Adva-27a molecule were unfavorable, prompting termination.
- IND-enabling studies of Adva-27a are paused pending chemical modification review.
- Company exploring chemical modification to address suboptimal performance in certain studies.
- No financial impact from termination disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823007582/0001683168-23-007582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823007582/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-007582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer